Decrease in Membranous NECTIN-4 Expression During Metastatic Spread of Urothelial Carcinoma and Association With Enfortumab Vedotin Resistance
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance
Clin. Cancer Res 2022 Dec 19;[EPub Ahead of Print], N Klümper, DJ Ralser, J Ellinger, F Roghmann, J Albrecht, E Below, A Alajati, D Sikic, J Breyer, C Bolenz, F Zengerling, P Erben, K Schwamborn, RM Wirtz, T Horn, D Nagy, M Toma, G Kristiansen, T Büttner, O Hahn, V Grünwald, C Darr, E Erne, S Rausch, J Bedke, K Schlack, M Abbas, S Zschäbitz, C Schwab, A Mustea, P Adam, A Manseck, B Wullich, M Ritter, A Hartmann, J Gschwend, W Weichert, F Erlmeier, M Hölzel, M EcksteinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.